+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastric Cancer - Pipeline Insight, 2021

  • ID: 4989187
  • Clinical Trials
  • July 2021
  • Region: Global
  • 60 Pages
  • DelveInsight
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Acepodia Biotech Inc.
  • BeiGene
  • Eisai
  • HiberCell, Inc.
  • Innovent Biologics
  • Merck Sharp & Dohme Corp.
This Gastric Cancer - Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Gastric Cancer Understanding


Gastric Cancer: Overview


Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It's also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer. The most common symptoms of stomach cancer include: difficulty swallowing (dysphagia), weight loss, indigestion (dyspepsia) that doesn't go away, feeling full after eating small amounts, feeling or being sick, and tiredness due to low red blood cells (anaemia). There are different types of treatment for patients with gastric cancer. Seven types of standard treatment are used: Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy.

Gastric Cancer - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gastric Cancer.

Gastric Cancer Emerging Drugs Chapters


This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastric Cancer Emerging Drugs


IBI308: Innovent Biologics

IBI308 is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.

HLX10: Henlix Biotech

It is a recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection independently researched and developed by Henlius, is for the treatment of various solid tumors and can be applied in combination with other products for immuno-oncology therapy. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.

Pamiparib: BeiGene

It is an investigational small molecule inhibitor of the PARP1 and PARP2 enzymes that is being evaluated as a potential monotherapy and in combination with other therapies to treat various solid tumors. Pamiparib's early compound name was BGB-290. Currently, it is in Phase II stage of clinical trial evaluation to treat gastric cancer.

Gastric Cancer: Therapeutic Assessment


This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Gastric Cancer


There are approx. 100+ key companies which are developing the therapies for Gastric Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.

Phases


This report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastric Cancer: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.

Gastric Cancer Report Insights

  • Gastric Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Gastric Cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Gastric Cancer drugs?
  • How many Gastric Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Gastric Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Innovent Biologics
  • Henlix Biotech
  • BeiGene
  • Hanmi Pharmaceutical Company Limited
  • Hutchison Medipharma Limited
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Russian Pharmaceutical Technologies
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Idience
  • AnewPharma
  • MedPacto, Inc.
  • Five Prime Therapeutics, Inc.
  • Genentech
  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd
  • Cellid Co., Ltd.
  • Nanjing Legend Biotech Co.
  • Eisai
  • Jiangsu Hengrui Medicine Co.
  • SYZ Cell Therapy Co.
  • LintonPharm Co.,Ltd.
  • Macrogenics
  • OncoTherapy Science
  • Avid Bioservices
  • Taizhou EOC Pharma Co., Ltd.
  • Bristol-Myers Squibb
  • Carsgen Therapeutics, Ltd.
  • Chengdu Kanghong Biotech Co., Ltd.
  • Ganymed Pharmaceuticals
  • Merck Sharp & Dohme Corp.
  • NextCure, Inc.
  • AstraZeneca
  • Pfizer
  • Pieris Pharmaceuticals, Inc.
  • Ambrx, Inc.
  • Merus N.V.
  • GeneQuantum Healthcare (Suzhou) Co., Ltd.
  • Highlight Therapeutics
  • Qilu Pharmaceutical Co., Ltd.
  • Green Cross Corporation
  • Imugene Limited
  • Vedanta Biosciences, Inc.
  • Acepodia Biotech Inc.
  • Keymed Biosciences Co.Ltd
  • Bold Therapeutics, Inc.
  • Regeneron Pharmaceuticals
  • Celon Pharma SA
  • Inhibrx, Inc.
  • HiberCell, Inc.
  • Treos Bio

Key Products

  • IBI308
  • HLX10
  • Pamiparib
  • FLX475
  • Volitinib
  • IBI-310
  • Anlotinib
  • Alofanib
  • DP303c
  • IDX-1197
  • HLX22
  • CM082
  • TEW-7197
  • Bemarituzumab
  • Atezolizumab
  • KN026
  • BVAC-B
  • LCAR-C18S
  • Lenvatinib
  • SHR6390
  • Camrelizumab
  • MASCT-I
  • Catumaxomab
  • INCMGA00012
  • OTSGC-A24
  • Bavituximab
  • Telatinib
  • BMS-986213
  • AB011
  • KH903
  • Zolbetuximab
  • Epacadostat
  • NC410
  • Durvalumab
  • Crizotinib
  • PRS-343
  • ARX788
  • MCLA-129
  • GQ1001
  • BO-112
  • QL1604
  • GC1118
  • IMU-131
  • VE800
  • ACE1702
  • CMG901
  • BOLD-100
  • 89Zr?DFO?REGN3504
  • CPL304110
  • INBRX-106
  • HC-5404-FU
  • PolyPEPI 1311
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acepodia Biotech Inc.
  • BeiGene
  • Eisai
  • HiberCell, Inc.
  • Innovent Biologics
  • Merck Sharp & Dohme Corp.
Introduction

Executive Summary

Gastric Cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  • Comparative Analysis
IBI308: Innovent Biologics
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Pamiparib: BeiGene
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
HC 5404 FU: HiberCell
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
PolyPEPI 1311: Treos Bio
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Gastric Cancer Key Companies

Gastric Cancer Key Products

Gastric Cancer- Unmet Needs

Gastric Cancer- Market Drivers and Barriers

Gastric Cancer- Future Perspectives and Conclusion

Gastric Cancer Analyst Views

Gastric Cancer Key Companies

Appendix

List of Tables
Table 1 Total Products for Gastric Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Gastric Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Innovent Biologics
  • Henlix Biotech
  • BeiGene
  • Hanmi Pharmaceutical Company Limited
  • Hutchison Medipharma Limited
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Russian Pharmaceutical Technologies
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Idience
  • AnewPharma
  • MedPacto, Inc.
  • Five Prime Therapeutics, Inc.
  • Genentech
  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd
  • Cellid Co., Ltd.
  • Nanjing Legend Biotech Co.
  • Eisai
  • Jiangsu Hengrui Medicine Co.
  • SYZ Cell Therapy Co.
  • LintonPharm Co.,Ltd.
  • Macrogenics
  • OncoTherapy Science
  • Avid Bioservices
  • Taizhou EOC Pharma Co., Ltd.
  • Bristol-Myers Squibb
  • Carsgen Therapeutics, Ltd.
  • Chengdu Kanghong Biotech Co., Ltd.
  • Ganymed Pharmaceuticals
  • Merck Sharp & Dohme Corp.
  • NextCure, Inc.
  • AstraZeneca
  • Pfizer
  • Pieris Pharmaceuticals, Inc.
  • Ambrx, Inc.
  • Merus N.V.
  • GeneQuantum Healthcare (Suzhou) Co., Ltd.
  • Highlight Therapeutics
  • Qilu Pharmaceutical Co., Ltd.
  • Green Cross Corporation
  • Imugene Limited
  • Vedanta Biosciences, Inc.
  • Acepodia Biotech Inc.
  • Keymed Biosciences Co.Ltd
  • Bold Therapeutics, Inc.
  • Regeneron Pharmaceuticals
  • Celon Pharma SA
  • Inhibrx, Inc.
  • HiberCell, Inc.
  • Treos Bio
Note: Product cover images may vary from those shown
Adroll
adroll